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1Atherosclerosis is a chronic disease with features of inflammation across the distinct stages of development.1 
Plaque rupture and erosion with ensuing thrombus formation 
and occlusion of the artery lead to acute clinical complica-
tions comprising acute coronary syndrome (ACS),2 which 
constitutes one of the leading causes of death worldwide.3 
Therefore, there is a great medical need to improve risk pre-
diction in asymptomatic patients,4 to improve early diagnosis 
and risk stratification of patients with ACS5 and to monitor 
atherosclerotic burden during treatment.
Proteins that are secreted or released from atherosclerotic 
lesions or thrombi into the circulation may provide a direct 
and simple measure of the atherosclerotic burden in individual 
patients. This concept has already been examined in the diag-
nosis and monitoring of other diseases, for example, several 
types of cancers by tumor markers.6
For the discovery of such biomarker candidates, we com-
bined gene expression profiling of coronary thrombi versus 
peripheral blood mononuclear cells and proteomic analysis 
of secretomes derived from atherosclerotic plaques versus 
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healthy tissue. The few differentially expressed transcripts and 
proteins identified by both approaches included fatty acid–
binding protein 4 (FABP4). Its expression in atherosclerotic 
plaques of carotid arteries was previously found to predict 
cardiovascular outcome7 or naturally occurring genetic low-
expression variant of FABP4 to promote plaque stability and 
to reduce the risk of cardiovascular events.8
We therefore selected FABP4 for clinical validation as a 
circulating biomarker and considered 3 different situations, 
where a novel cardiovascular biomarker may improve clini-
cal management of coronary artery disease (CAD). In clini-
cal routine, electrocardiography and cardiac troponins are the 
gold standards for making the diagnosis of ACS.9 As the trade-
off of their high sensitivity, novel cardiac troponin assays have 
reduced specificity,10 what may be improved by the determi-
nation of additional biomarkers reflecting plaque rupture. For 
this reason, we assessed in a cross-sectional study (designated 
as the diagnostic cohort) diagnostic performance of FABP4 
by comparing circulating FABP4 levels of healthy individu-
als with those of patients with stable CAD or ACS. Another 
medical need is an improvement of risk prediction toward 
optimized or personalized targeting of preventive measures. 
Clinical risk prediction algorithms combining demographic, 
clinical, and biochemical measures are nowadays reference 
methods; however, they differ considerably in primary and 
secondary prevention settings. For instance, for primary pre-
vention in an asymptomatic population, algorithms and scores, 
such as Framingham, Pooled Cohort Equations, or European 
Atherosclerosis Society/European Society of Cardiology 
score combine information on age and sex with risk factors, 
such as diabetes mellitus, blood pressure, and plasma lip-
ids.11 For secondary prevention of symptomatic patients, the 
GRACE or thrombolysis in myocardial infarction scores com-
bine data on age, cardiovascular, and renal function.12 In our 
study, we assessed the performance of circulating FABP4 as a 
prognostic biomarker for the incidence of cerebrovascular and 
cardiovascular events in 2 nested case–control studies: 1 with 
5-year follow-up of asymptomatic individuals from the gen-
eral population (designated as prospective population cohort) 
and another with 30-day follow-up of patients with ACS (des-
ignated as prospective clinical cohort).
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Identification of FABP4 as a Biomarker Candidate
Data sets from 2 independent approaches were combined to 
identify biomarker candidates for CAD. In the first approach, 
using gene array technology, mRNA expression levels isolated 
from coronary thrombi were compared with those of periph-
eral blood mononuclear cells from patients with ACS. In the 
second approach, protein profiles of atherosclerotic plaque–
derived secretomes were compared with those of healthy tis-
sue secretomes from the corresponding endarterectomized 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
AUC area under the curve
BMI body mass index
CAD coronary artery disease
CI confidence interval
FABP4 fatty acid-binding protein 4
NT-proBNP N-terminal pro–brain natriuretic peptide
OR odds ratio
STEMI ST-segment–elevation myocardial infarction
Table 1.  Characteristics of the Diagnostic Cohort
Characteristics Controls, n=313 CAD, n=68 NSTEMI, n=170 STEMI, n=269 P Value
Age, y 60±10 62±7 64±13 63±12 <0.001
Sex, male* 214 (68%) 59 (87%) 137 (81%) 207 (77%) 0.001
Hypertension* 159 (51%) 61 (90%) 136 (80%) 184 (68%) <0.001
Hypercholesterolemia* 155 (50%) 58 (85%) 124 (73%) 179 (67%) <0.001
T2DM* 38 (12%) 22 (32%) 52 (31%) 152 (57%) <0.001
Current smoking* 103 (33%) 9 (13%) 73 (43%) 109 (41%) <0.001
Body mass index, kg/m2 27±4 29±5 27±4 27±5 0.034
Total cholesterol, mmol/L 5.8±1.0 4.1±1.1 4.9±1.2 5.1±1.2 <0.001
HDL, mmol/L 1.6±0.4 1.1±0.4 1.1±0.4 1.2±0.3 <0.001
LDL, mmol/L 3.6±0.9 2.3±0.8 3.1±1.1 3.4±1.6 <0.001
Triglycerides, mmol/L† 1.3 (0.6–3.0) 1.0 (0.5–4.4) 1.3 (0.5–3.5) 0.9 (0.4–2.6) <0.001
CRP, mg/L† 1.5 (0.3–8.3) 0.9 (0.3–15.0) 3.6 (0.5–43.5) 2.2 (0.4–35.7) <0.001
hsTnT, µg/L† n.d. n.d. 0.47 (0.015–3.06) 0.22 (0.12–3.34) 0.002
Glucose, mmol/L† 5.6 (4.6–8.1) 5.6 (4.3–11.2) 6.0 (4.6–11.7) 7.4 (5.2–17.2) <0.001
FABP4, ng/mL† 23.4 (5.9–71.0) 22.5 (7.4–73.7) 20.3 (8.8–70.2) 24.9 (10.0–77.9) 0.029
CAD indicates coronary artery disease; CRP, C-reactive protein; FABP4, fatty acid–binding protein 4; HDL, high-density 
lipoprotein; hsTnT, high-sensitive troponin T; LDL, low-density lipoprotein; NSTEMI, non–ST-segment–elevation myocardial 
infarction; NT-proBNP, N-terminal pro–brain natriuretic peptide; STEMI, ST-segment–elevation myocardial infarction; and T2DM, 
diabetes mellitus type 2.
*n (%), χ2 test.
†Median (5th–95th percentile), Mann–Whitney U test.
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carotid arteries.13 Comparison of 325 upregulated mRNAs 
from coronary thrombi with 390 proteins from the secre-
tomes (Table I in the online-only Data Supplement) yielded 
8 common hits. The FABP4 was the only protein detected in 
the plaque secretomes, but not in the control secretomes, its 
mRNA expression in coronary thrombi was 55-fold higher 
than in peripheral blood mononuclear cells (Table II in the 
online-only Data Supplement). Moreover, increased FABP4 
expression in atherosclerotic plaques of carotid arteries was 
found to predict forthcoming adverse cardiovascular events.7 
Therefore, FABP4 was selected for clinical validation.
FABP4 Confounding Factors and Correlation 
With Other Diagnostic Parameters
In both the diagnostic and the prospective population cohort, 
bivariate analysis revealed weak to moderately positive cor-
relations of circulating FABP4 with age, body mass index 
(BMI), glucose, and C-reactive protein. Notably, FABP4 in 
the diagnostic cohort showed stronger correlation with BMI in 
asymptomatic controls than in CAD patients (P=0.34 versus 
0.22, both P value <0.001). There was no significant corre-
lation of FABP4 with total cholesterol, high-density lipopro-
tein, low-density lipoprotein, or triglycerides in either cohort 
(Table III in the online-only Data Supplement). In general, 
circulating FABP4 levels were significantly higher in women, 
in individuals with BMI >25 kg/m2, diabetes mellitus, or with 
hypertension when compared with men, normal weight, non-
diabetic, and normotensive counterparts. Circulating FABP4 
was lower in current smokers than in nonsmokers, but this 
difference was only significant in the diagnostic cohort (Table 
IV in the online-only Data Supplement).
Furthermore, circulating FABP4 showed a very weak pos-
itive correlation with high-sensitive troponin T (P=0.19 and 
0.01) or C-reactive protein (P=0.16 and 0.04) in the diagnostic 
cohort. In the prospective clinical cohort, circulating FABP4 
moderately correlated with the GRACE risk score for in-
hospital death or myocardial infarction (P=0.41 and <0.001), 
with N-terminal pro–brain natriuretic peptide (NT-proBNP; 
P=0.35 and <0.001) and with creatinine (P=0.45 and <0.001; 
Table V in the Data Supplement).
Circulating FABP4 Levels Do Not Differ 
Remarkably Between Patients With 
ACS and Asymptomatic Controls
The cross-sectional diagnostic cohort included 820 indi-
viduals from both SPUM-ACS (n=553) and CoLaus studies 
(n=267). The SPUM-ACS participants were recruited at the 
University Hospital Zurich and included 46 healthy controls, 
68 patients with stable CAD, 269 patients with ST-segment–
elevation myocardial infarction (STEMI), and 170 patients 
with non–ST-segment–elevation myocardial infarction. Since 
the number of healthy controls was low in the SPUM-ACS 
study and these individuals were younger than patients with 
CAD (data not shown), additional controls were selected from 
the CoLaus study cohort. Detailed clinical and laboratory 
characteristics are shown in Table 1.
One-factorial ANOVA with Games–Howell correction 
was applied for multiple comparisons of circulating FABP4 in 
Figure 1. Odds ratios (ORs) for associations of risk factors and circulating fatty acid–binding protein 4 (FABP4) with different clinical 
manifestations of acute coronary syndrome in the diagnostic cohort. Multivariate logistic regression models with adjustment for several 
confounding factors, such as sex (male), age (years), BMI (body mass index; kg/m2), hypertension, or diabetes mellitus, were used. Plots 
show odds ratios with corresponding 95% confidence intervals (CIs) and P values for the 1-SD changes in the log-transformed FAPB4, 
and 1-SD changes in the age and BMI (Wald statistics). Models for controls vs ST-segment–elevation myocardial infarction (STEMI; A and 
B) and non–STEMI vs STEMI (C and D). The vertical reference line indicates an OR of 1.0. T2DM indicates diabetes mellitus type 2.
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asymptomatic controls, patients with stable CAD and patients 
with ACS, respectively. Circulating FABP4 was significantly 
higher (P=0.01) in patients with STEMI (median 24.9 ng/mL 
with 5th–95th percentile range, 11.0–77.9) compared with 
asymptomatic controls (median 23.4 ng/mL with 5th–95th 
percentile range, 5.9–71.0). Other groups did not differ signif-
icantly from each other with respect to the circulating FABP4.
The difference in the circulating FABP4 between patients 
with STEMI and asymptomatic controls remained significant 
after adjustment for age, sex, and BMI (odds ratio [OR], 1.3; 
95% confidence interval [CI], 1.1–1.6; P=0.004). However, 
this significance was lost after further adjustment for diabetes 
mellitus and hypertension (OR, 1.2; 95% CI, 1.0–1.5; P=0.1). 
In contrary, differences in the circulating FABP4 between 
patients with STEMI and non–ST-segment–elevation myocar-
dial infarction became statistically significant in both adjusted 
models (OR, 1.4; 95% CI, 1.1–1.8; P=0.003 and OR, 1.4; 95% 
CI, 1.1–1.8; P=0.01). The details of logistic regression models 
are presented in Figure 1. No other differences in the circulat-
ing FABP4 became statistically significant after adjustment 
for the confounding factors.
Circulating FABP4 Predicts the Occurrence of 
Adverse Cerebrovascular and Cardiovascular 
Events in Patients With ACS
The prognostic performance of circulating FABP4 for future 
cerebrovascular or cardiovascular events was assessed in a 
nested case–control study of 200 patients with ACS from 4 
hospitals participating in the SPUM-ACS study. These patients 
had a primary diagnosis of unstable angina (n=12), STEMI 
(n=106), or non–ST-segment–elevation myocardial infarc-
tion (n=82). During 30-day follow-up, 70 patients developed 
adjudicated cerebrovascular and cardiovascular events: death 
(34 cardiac deaths and 3 unclear deaths), recurrent myocardial 
infarction (n=22), or stroke (n=11). Cases were matched for 
age, sex, and center with 130 patients who survived 30 days 
without any event (Table 2).
Circulating FABP4 was significantly higher in patients 
who developed adverse cerebrovascular and cardiovascular 
events during the follow-up compared with control patients 
without any event: 39.9 ng/mL (5th–95th percentile range, 
15.0–307.7) versus 26.4 ng/mL (5th–95th percentile range, 
13.8–97.9), respectively, P=0.001. These differences remained 
statistically significant after adjustment for age, sex, creatinine 
level, and BMI (OR, 1.7; 95% CI, 1.1–2.5; P=0.02; Figure 2).
The prognostic performance of FABP4 for predicting 
adverse cerebrovascular or cardiovascular events during 
the follow-up was further assessed by comparison with the 
GRACE risk score (predictor for in-hospital death or myocar-
dial infarction) and NT-proBNP levels. On Cox proportional 
hazard analysis, FABP4 (hazard ratio, 1.40; 95% CI, 1.04–
1.87; P=0.026), GRACE risk score (hazard ratio, 1.44; 95% 
CI, 1.08–1.92; P=0.014), and NT-proBNP (hazard ratio, 1.35; 
95% CI, 1.02–1.81; P=0.039) almost equally contributed to 
Table 2. Matching for Controls and Cases in the Prospective Clinical Cohort 
of Patients With Acute Coronary Syndrome During 30-d Follow-Up (n=200)
Characteristic Controls, n=130 Cases, n=70 P Value
Clinical presentation*
  UA 8 (6%) 4 (6%) 0.20
  NSTEMI 59 (45%) 23 (33%)
  STEMI 63 (49%) 43 (61%)
Age, y 71±12 72±11 0.71
Sex, male* 91 (70%) 50 (71%) 0.83
Hypertension* 95 (73%) 46 (66%) 0.28
T2DM* 24 (18.5%) 21 (30%) 0.06
Current smoking* 31 (24%) 23 (33%) 0.13
BMI, kg/m2 27±4 27±5 0.26
Total cholesterol, mmol/L 4.7±1.3 4.5±1.2 0.38
HDL, mmol/L 1.2±0.4 1.2±0.3 0.59
LDL, mmol/L 2.9±1.2 2.8±1.0 0.93
Triglycerides, mmol/L 1.3±0.8 1.1±0.7 0.11
CRP, mg/L† 2.9 (0.5–73.5) 5.8 (0.4–97.9) 0.04
hsTnT, µg/L† 0.306 (0.012–3.008) 0.743 (0.018–5.323) 0.01
NT-proBNP, ng/L† 797 (43–7314) 1340 (76–28 094) 0.01
Creatinine, µmol/L† 77.0 (52.5–142.7) 88.5 (56.2–202.7) 0.001
FABP4, ng/mL† 26.4 (13.8–97.9) 39.9 (15.0–307.7) 0.001
In-hospital death or myocardial 
infarction GRACE score
212±50 248±68 <0.001
BMI indicates body mass index; CRP, C-reactive protein; FABP4, fatty acid–binding protein 
4; HDL, high-density lipoprotein; hsTnT, high-sensitive troponin T; LDL, low-density lipoprotein; 
NSTEMI, non–ST-segment–elevation myocardial infarction; NT-proBNP, N-terminal pro–brain 
natriuretic peptide; STEMI, ST-segment–elevation myocardial infarction; T2DM, diabetes mellitus 
type 2; and US, unstable angina.
*n (%), χ2 test.
†Median (5th–95th percentile), Mann–Whitney U test.
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the prediction of adverse events during the 30-day follow-up. 
The receiver operating characteristic analysis of FABP4 as a 
prognostic marker revealed an area under the curve (AUC) of 
0.65 (95% CI, 0.56–0.75; P=0.001), which was nearly identi-
cal to that obtained for the GRACE risk score (AUC, 0.67; 
95% CI, 0.57–0.76; P<0.001). The combination of FABP4 
and GRACE scores did not further improve the prediction 
of the outcome (AUC, 0.67; 95% CI, 0.57–0.76; P<0.001). 
The AUC for NT-proBNP (AUC, 0.61; 95% CI, 0.53–0.71; 
P=0.045) was lower, but the combination of FABP4 and 
NT-proBNP reached the highest AUC of 0.68 (95% CI, 0.60–
0.77; P=0.045; Figure 3).
Circulating FABP4 at Baseline Does Not 
Predict the Development of Cardiovascular 
Events in the Asymptomatic Population
The prognostic performance of circulating FABP4 for future 
cardiovascular events was assessed in the prospective nested 
case–control cohort of 414 asymptomatic participants from 
the population-based CoLaus study. During 5-year follow-
up, 112 individuals experienced an adjudicated cardiovascu-
lar event: 22 cardiovascular deaths, 54 myocardial infarction, 
and 36 symptomatic CAD followed by percutaneous or surgi-
cal revascularization. These cases were matched by sex, age, 
and health status with 302 controls who did not manifest any 
CAD event (Table 3). No significant difference in circulating 
FABP4 was found between individuals with or without inci-
dence of cardiovascular event: 23.7 ng/mL (5th–95th percen-
tile range, 5.9–76.8) versus 23.3 ng/mL (5th–95th percentile 
range, 9.3–71.4), P=0.75.
Discussion
The purpose of this project was the identification of novel 
CAD biomarkers by integration of proteomic and gene 
expression profiling data sets obtained from atherosclerotic 
plaque secretomes and coronary thrombi, respectively. The 
proteomic study aimed for the identification of proteins that 
are released from the plaque into the circulation during the 
progression or rupturing of atherosclerotic plaque. We previ-
ously showed that the composition and phenotype of mononu-
clear cells in coronary thrombi differ significantly from those 
of peripheral blood mononuclear cells obtained from patients 
with ACS.14,15 Therefore, differential gene expression profiling 
was performed to identify molecular characteristics of throm-
bus-associated mononuclear cells that could also serve as ACS 
biomarkers. Comparison of both data sets revealed several 
common targets. One of them, FABP4 (also known as AFABP 
or aP2) was found in the plaque secretome but not in the con-
trol secretome and its expression in coronary thrombi was 
55-fold higher than in peripheral blood mononuclear cells.
FABP4 is abundantly produced in adipocytes, but sig-
nificant amounts of FABP4 are also found in macrophages, 
which are pathogenic constituents of atherosclerotic plaques. 
Furthermore, a naturally occurring genetic low-expression vari-
ant of FABP4 was found to promote plaque stability and reduce 
the risk of cardiovascular events.8 On the contrary, FABP4 
expression is increased in vulnerable and ruptured plaques as 
shown by genome-wide expression analysis of isolated mac-
rophages16 and quantification of FABP4 in vulnerable human 
plaques.7 Extensive studies in FABP4-deficient mice or FABP4 
inhibitor–treated animals also demonstrated that FABP4 pro-
motes insulin resistance and the development of diabetes melli-
tus and modulates lipid metabolism.17 Moreover, FABP4 seems 
Figure 2. Odds ratios (ORs) for associations of confounding 
factors and circulating fatty acid–binding protein 4 (FABP4) in 
patients with adverse cerebrovascular and cardiovascular events 
during 30-day follow-up after the index acute coronary syndrome 
event. Multivariate logistic regression model with adjustment for 
several confounding factors, such as sex (male), age (years), BMI 
(body mass index; kg/m2), and creatinine (μmol/L) were used. Plot 
shows ORs with corresponding 95% confidence intervals (CIs) 
and P values for the 1-SD changes in the log-transformed FAPB4 
and creatinine values, and 1-SD changes in the age and BMI 
(Wald statistics). The vertical reference line indicates an OR of 1.0.
Figure 3. Fatty acid–binding protein 4 (FABP4) predicts adverse 
cerebrovascular and cardiovascular events during 30-day 
follow-up after an index acute coronary syndrome event. A, The 
calculated areas under the curve (AUCs) for FABP4, GRACE risk 
score, and their combination as predictors of adverse events 
was 0.65 (95% confidence interval [CI], 0.56–0.75; P=0.001), 
0.67 (95% CI, 0.57–0.76; P<0.001), and 0.67 (95% CI, 0.57–0.76; 
P<0.001), respectively. B, The calculated AUCs for N-terminal 
pro–brain natriuretic peptide (NT-proBNP) was 0.61 (95% CI, 
0.53–0.71; P=0.045) and for the combination of FABP4 and NT-
proBNP was 0.68 (95% CI 0.60–0.77, P=0.045).
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to play an important role in the development of atherosclerosis. 
For instance, in the absence of any significant differences in 
serum lipids and insulin sensitivity, FABP4/ApoE-double–
knockout mice developed markedly less atherosclerosis than 
control ApoE-knockout mice. Interestingly, the reduction of 
atherosclerotic lesions was similar in macrophage-specific 
FABP4 deficiency and whole-body FABP4-deficient mice.18 
These data indicate that macrophage-derived FABP4 may exert 
local pathogenic effects in atherosclerosis independent from its 
established role in systemic glucose or lipid metabolism.
Therefore, we selected FABP4 for further validation as a 
diagnostic and prognostic biomarker for atherosclerotic CAD. 
Our validation studies confer 3 major findings on circulating 
FABP4 as a diagnostic and prognostic biomarker.
Firstly, circulating FABP4 was not associated in a clini-
cally meaningful manner with the presence of stable CAD 
or its acute manifestations. In line with our results, Cabré et 
al19 demonstrated that circulating FABP4 levels are not sig-
nificantly associated with clinical or subclinical atheroscle-
rosis but are markedly increased in patients with metabolic 
syndrome. In contrast to the studies in whites, several studies 
in Asian populations showed significant associations of cir-
culating FABP4 with CAD. For instance, circulating FABP4 
correlated positively with carotid intima-media thickness 
in Chinese women,20 with atherosclerotic burden measured 
by intravascular ultrasound,21 or with CAD in nonelderly 
Japanese men.22 These discrepant findings between white and 
Asian populations on the association of circulating FABP4 
with CAD might be partially explained by different genetic 
and environmental background. For instance, the prevalence 
of hypertension, hypercholesterolemia, or overweight and 
obesity is higher in whites than in Asians.23,24 It has to be noted 
that these conditions are associated with higher FABP4 levels, 
as found in this and other studies.25,26
Secondly, circulating FABP4 was significantly elevated in 
patients with ACS who experienced adverse cerebrovascular 
or cardiovascular events within 30 days after the index ACS 
event. Furthermore, FABP4 showed the same prognostic power 
to predict adverse events as the GRACE in-hospital risk score 
or NT-proBNP. Although the highest concentration of FABP4 
was observed in patients with ACS who experienced cardiac 
death (data not shown), our nested cohort is too small to claim 
a differential prognostic role of FABP4 in the prediction of fatal 
and nonfatal events. It is interesting to note that a significant 
association of FABP4 with cerebrovascular or cardiovascular 
events was also observed in a prospective 10-year long follow-
up study of patients with CAD.27 In this study, high baseline 
levels of FABP4 were associated with a higher risk for subse-
quent adverse events in unadjusted analyses and significantly 
predicted cardiovascular death even after adjustment for estab-
lished cardiovascular risk factors and lipid-lowering drugs.
Finally, circulating FABP4 had no association with inci-
dence of cardiovascular events in our prospective population 
cohort. In a similar study of Hong Kong Chinese, circulating 
FABP4 was found to predict the development of CAD after 
adjustment for the traditional risk factors. Despite independent 
association with an integrated discrimination improvement of 
0.25%, FABP4 helped only marginally to improve the perfor-
mance of the predictive model with established risk factors.28
The following limitations of our study have to be consid-
ered. Our data do not imply any causal relationship between 
circulating FABP4 and development of adverse events after 
the index ACS. The sample size of our prospective clinical 
cohort was rather modest, and additional studies with larger 
numbers are required to confirm our findings and to validate 
the prognostic performance of FABP4.
In conclusion, circulating FABP4 was associated with 
neither stable CAD nor ACS, and thus is unlikely to serve 
as a clinically relevant diagnostic biomarker. Neither does it 
seem to be a relevant predictive biomarker in an asymptomatic 
population. However, in patients with ACS, FABP4 may serve 
as a prognostic marker to identify patients at risk for adverse 
cerebrovascular or cardiovascular events.
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Table 3. Matching Controls and Cases in the Prospective 
Population Cohort During 5-y Follow-Up (n=414)
Variable Controls, n=302 Cases, n=112 P Value
Age, y 60.9±9.8 61.2±9.4 0.77
Sex, men* 208 (69%) 81 (70%) 0.50
Hypertension* 185 (61%) 70 (63%) 0.82
T2DM* 43 (14%) 21 (19%) 0.26
Current smoking* 118 (39%) 41 (37%) 0.65
BMI, kg/m2 27.9±4.6 28.4±5.4 0.38
Total cholesterol, mmol/L 5.8±1.1 5.7±1.0 0.18
HDL, mmol/L 1.5±0.4 1.4±0.4 0.03
LDL, mmol/L 3.6±1.0 3.5±0.9 0.23
Triglycerides, mmol/L 1.6±0.8 1.7±0.9 0.10
hsCRP, mg/L† 1.7 (0.4–10.5) 2.3 (0.3–17.3) 0.04
FABP4, ng/mL† 23.7 (5.9–76.8) 23.3 (9.3–71.4) 0.75
BMI indicates body mass index; FABP4, fatty acid–binding protein 4; HDL, 
high-density lipoprotein; hsCRP, high-sensitive C-reactive protein; LDL, low-
density lipoprotein; and T2DM, diabetes mellitus type 2.
*n (%), χ2 test.
†Median (5th–95th percentile), Mann–Whitney U test.
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Blood-borne biomarkers reflecting atherosclerotic plaque burden have great potential to improve the clinical management of atherosclerotic 
coronary artery disease and acute coronary syndromes. Fatty acid–binding protein 4 was identified as a biomarker candidate using data inte-
gration from gene expression profiling of coronary thrombi versus peripheral blood mononuclear cells and proteomic analysis of atheroscle-
rotic plaque–derived secretomes versus healthy tissue–derived secretomes. In general, elevated fatty acid–binding protein 4 is associated 
with the incidence (of adverse secondary cerebrovascular or cardiovascular events during 30-day follow-up after the index acute coronary 
syndrome, independent of age, sex, renal function, and body mass index. Moreover, fatty acid–binding protein 4 predicts adverse events with 
similar prognostic performance as the GRACE in-hospital risk score or N-terminal pro–brain natriuretic peptide. Circulating fatty acid–binding 
protein 4 may prove useful as a prognostic biomarker in risk stratification of patients with acute coronary syndrome.
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